369 related articles for article (PubMed ID: 29720435)
1. Cost-Effectiveness of Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Stroke Prevention.
Leppert MH; Poisson SN; Carroll JD; Thaler DE; Kim CH; Orjuela KD; Ho PM; Burke JF; Campbell JD
Stroke; 2018 Jun; 49(6):1443-1450. PubMed ID: 29720435
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the cost-effectiveness of percutaneous closure of a patent foramen ovale versus medical management in patients with a cryptogenic stroke: from the UK payer perspective.
Hildick-Smith D; Turner M; Shaw L; Nakum M; Hartaigh BÓ; Evans RM; Rhodes JF; Sondergaard L; Kasner SE
J Med Econ; 2019 Feb; 22(2):131-139. PubMed ID: 30424680
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of percutaneous patent foramen ovale closure as secondary stroke prevention.
Tirschwell DL; Turner M; Thaler D; Choulerton J; Marks D; Carroll J; MacDonald L; Smalling RW; Koullick M; Gu NY; Saver JL
J Med Econ; 2018 Jul; 21(7):656-665. PubMed ID: 29564942
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of patent foramen ovale closure versus medical therapy alone after cryptogenic stroke.
Shijoh Y; Saito S; Dai Z; Ohde S
PLoS One; 2022; 17(6):e0268690. PubMed ID: 35657973
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of percutaneous closure of a patent foramen ovale compared with medical management in patients with a cryptogenic stroke: from the US payer perspective.
Volpi JJ; Ridge JR; Nakum M; Rhodes JF; Søndergaard L; Kasner SE
J Med Econ; 2019 Sep; 22(9):883-890. PubMed ID: 31025589
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness analysis of patent foramen ovale closure with Amplatzer plus medical therapy compared to medical therapy in patients with a history of stroke in France.
Allou A; Baschet L; Sabourin C; Montalscot G; Lorgis L; Iriart X
J Cardiol; 2022 Jul; 80(1):72-79. PubMed ID: 34772575
[TBL] [Abstract][Full Text] [Related]
7. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.
Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC
Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of percutaneous closure versus medical therapy for cryptogenic stroke in patients with a patent foramen ovale.
Pickett CA; Villines TC; Ferguson MA; Hulten EA
Am J Cardiol; 2014 Nov; 114(10):1584-9. PubMed ID: 25248812
[TBL] [Abstract][Full Text] [Related]
9. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
[TBL] [Abstract][Full Text] [Related]
10. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
Wiktor DM; Carroll JD
Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
[TBL] [Abstract][Full Text] [Related]
11. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis.
Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA
JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929
[TBL] [Abstract][Full Text] [Related]
12. Propensity Score-Based Analysis of Percutaneous Closure Versus Medical Therapy in Patients With Cryptogenic Stroke and Patent Foramen Ovale: The IPSYS Registry (Italian Project on Stroke in Young Adults).
Pezzini A; Grassi M; Lodigiani C; Patella R; Gandolfo C; Zini A; DeLodovici ML; Paciaroni M; Del Sette M; Toriello A; Musolino R; Calabrò RS; Bovi P; Adami A; Silvestrelli G; Sessa M; Cavallini A; Marcheselli S; Marco Bonifati D; Checcarelli N; Tancredi L; Chiti A; Del Zotto E; Tomelleri G; Spalloni A; Giorli E; Costa P; Giacalone G; Ferrazzi P; Poli L; Morotti A; Piras V; Rasura M; Simone AM; Gamba M; Cerrato P; Zedde ML; Micieli G; Melis M; Massucco D; Guido D; De Giuli V; Bonaiti S; D'Amore C; La Starza S; Iacoviello L; Padovani A;
Circ Cardiovasc Interv; 2016 Sep; 9(9):. PubMed ID: 27582111
[TBL] [Abstract][Full Text] [Related]
13. Risk of Paradoxical Embolism (RoPE)-Estimated Attributable Fraction Correlates With the Benefit of Patent Foramen Ovale Closure: An Analysis of 3 Trials.
Kent DM; Saver JL; Ruthazer R; Furlan AJ; Reisman M; Carroll JD; Smalling RW; Jüni P; Mattle HP; Meier B; Thaler DE
Stroke; 2020 Oct; 51(10):3119-3123. PubMed ID: 32921262
[TBL] [Abstract][Full Text] [Related]
14. Patent foramen ovale closure vs. medical therapy alone after cryptogenic stroke in China: A cost-effectiveness analysis.
Wei N; Liu B; Ma M; Zhang X; Zhang W; Hou F; Liu F; Yu X
Front Public Health; 2022; 10():1016854. PubMed ID: 36407985
[TBL] [Abstract][Full Text] [Related]
15. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.
Rengifo-Moreno P; Palacios IF; Junpaparp P; Witzke CF; Morris DL; Romero-Corral A
Eur Heart J; 2013 Nov; 34(43):3342-52. PubMed ID: 23847132
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Percutaneous Patent Foramen Ovale Closure Preventing Secondary Ischemic Stroke in Japan.
Inoue S; Igarashi A; Iguchi Y; Akagi T
J Stroke Cerebrovasc Dis; 2021 Aug; 30(8):105884. PubMed ID: 34153592
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness and clinical efficacy of patent foramen ovale closure as compared to medical therapy in cryptogenic stroke patients: A detailed cost analysis and meta-analysis of randomized controlled trials.
Pickett CA; Villines TC; Resar JR; Hulten EA
Int J Cardiol; 2018 Dec; 273():74-79. PubMed ID: 30119914
[TBL] [Abstract][Full Text] [Related]
18. Patent foramen ovale (PFO) closure versus medical therapy for prevention of recurrent stroke in patients with prior cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials.
Akobeng AK; Abdelgadir I; Boudjemline Y; Hijazi ZM
Catheter Cardiovasc Interv; 2018 Jul; 92(1):165-173. PubMed ID: 29602258
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials.
Abdelaziz HK; Saad M; Abuomara HZ; Nairooz R; Pothineni NVK; Madmani ME; Roberts DH; Mahmud E
Catheter Cardiovasc Interv; 2018 Jul; 92(1):176-186. PubMed ID: 29726616
[TBL] [Abstract][Full Text] [Related]
20. The role of device closure of patent foramen ovale in patients with cryptogenic stroke.
Fukutomi M; Wilkins B; Søndergaard L
J Intern Med; 2020 Oct; 288(4):400-409. PubMed ID: 32812297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
